Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 218

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Open access
Heerspink, Hiddo J L, Stefansson, Bergur V, Chertow, Glenn M, Correa-Rotter, Ricardo, Greene, Tom, Hou, Fan-Fan, Lindberg, Magnus, McMurray, John, Rossing, Peter, Toto, Roberto, Langkilde, Anna Maria, Wheeler, David C, for the DAPA-CKD Investigators, Heerspink, H J L, Wheeler, D C, Chertow, G, Correa-Rotter, R, Greene, T, Hou, F-F, McMurray, J, Rossing, P, Toto, R, Stefansson, B, Langkilde, A M, Pfeffer, Marc A, Pocock, Stuart, Swedberg, Karl, Rouleau, Jean L, Chaturvedi, Nishi, Ivanovich, Peter, Levey, Andrew S, Christ-Schmidt, Heidi, Mann, Johannes, Held, Claes, Varenhorst, Christoph, Holmgren, Pernilla, Hallberg, Theresa, Douthat, Walter, Filho, Roberto Pecoits, Cherney, David, Hou, Fan Fan, Persson, Frederik, Haller, Hermann, Wittmann, István, Tudományegyetem, Pécsi, Khullar, Dinesh, Naoki, Kashihara, Correa-Rotter, Richardo, Escudero, Elizabeth, Isidto, Rey, Iloilo, Healthlink, Nowicki, Michal, Batiushin, Mikhail, Kang, Shin-Wook, Teruel, José Luis Górriz, Furuland, Hans, Bilchenko, Oleksandr, Mark, Patrick, Dwyer, Jamie, Van Bui, Pham · 2020 · Nephrology Dialysis Transplantation

Abstract

Background: Recent cardiovascular outcome trials have shown that sodium–glucose co-transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes at high cardiovascular risk. Whether these benefits extend to CKD patients without type 2 diabetes or cardiovascular disease is unknown. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial (NCT03036150) will assess the effect of the SGLT2 inhibitor dapagliflozin on renal and cardiovascular events in a broad range of patients with CKD with and without diabetes. Methods: DAPA-CKD is a randomized, double-blind, placebo-controlled, trial in which ∼4300 patients with CKD Stages 2–4 and elevated urinary albumin excretion will be enrolled. The vast majority will be receiving a maximum tolerated dose of a renin–angiotensin system inhibitor at enrolment. Results: After a screening assessment, eligible patients with a urinary albumin:creatinine ratio ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 are randomly assigned to placebo or dapagliflozin 10 mg/day. Enrolment is monitored to ensure that at least 30% of patients do not have diabetes and that no more than 10% have an eGFR >60 mL/min/1.73 m2. The primary endpoint is a composite of a sustained decline in eGFR of ≥50%, end-stage renal disease, renal death or cardiovascular death. The trial will conclude when 681 primary renal events have occurred, providing 90% power to detect a 22% relative risk reduction (α level of 0.05). Conclusion: DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfz290

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 5

  1. Dekkers, 2018, New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors, Curr Diab Rep, 18, 27, 10.1007/s11892-018-0992-6 · DOI
  2. Rajasekeran, 2017, Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?, Curr Opin Nephrol Hypertens, 26, 358, 10.1097/MNH.0000000000000343 · DOI
  3. Komoroski, 2009, Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects, Clin Pharmacol Ther, 85, 520, 10.1038/clpt.2008.251 · DOI · Paper page
  4. Al Jobori, 2017, Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients, Diabetes Obes Metab, 19, 809, 10.1111/dom.12881 · DOI
  5. Pleros, 2018, Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report, CEN Case Rep, 7, 17, 10.1007/s13730-017-0283-0 · DOI

Cited by

See all 218

Metadata

Authors
Heerspink, H. J. L., Stefansson, B. V., Chertow, G. M., Correa-Rotter, R., Greene, T., Hou, F.-F., Lindberg, M., McMurray, J., Rossing, P., Toto, R., Langkilde, A. M., Wheeler, D. C., for the DAPA-CKD Investigators, Heerspink, H. J. L., Wheeler, D. C., Chertow, G., Correa-Rotter, R., Greene, T., Hou, F.-F., McMurray, J., Rossing, P., Toto, R., Stefansson, B., Langkilde, A. M., Pfeffer, M. A., Pocock, S., Swedberg, K., Rouleau, J. L., Chaturvedi, N., Ivanovich, P., Levey, A. S., Christ-Schmidt, H., Mann, J., Held, C., Varenhorst, C., Holmgren, P., Hallberg, T., Douthat, W., Filho, R. P., Cherney, D., Hou, F. F., Persson, F., Haller, H., Wittmann, I., Tudományegyetem, P., Khullar, D., Naoki, K., Correa-Rotter, R., Escudero, E., Isidto, R., Iloilo, H., Nowicki, M., Batiushin, M., Kang, S.-W., Teruel, J. L. G., Furuland, H., Bilchenko, O., Mark, P., Dwyer, J., & Van Bui, P.
Venue
Nephrology Dialysis Transplantation
Published
2020-02-01
Volume
35
Issue
2
Pages
274-282
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W3005350465
Cited by
218
References
8
FWCI
26.24
Type
journal article
Language
en
Open access
hybrid
Funders
AstraZeneca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. https://app.cochat.ai/papers/10.1093/ndt/gfz290
The paper
Heerspink, H. J. L., Stefansson, B. V., Chertow, G. M., Correa-Rotter, R., Greene, T., Hou, F.-F., Lindberg, M., McMurray, J., Rossing, P., Toto, R., Langkilde, A. M., Wheeler, D. C., for the DAPA-CKD Investigators, Heerspink, H. J. L., Wheeler, D. C., Chertow, G., Correa-Rotter, R., Greene, T., Hou, F.-F., . . . Van Bui, P. (2020). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfz290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.